Drug Trial Radar · NCT06211764
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
272
Actual
Start
Apr 9, 2024
Primary completion
Nov 27, 2030
Study completion Apr 14, 2031
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Conditions
- Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-200Drug
Participants will receive TAR-200 intravesically.
Mitomycin CDrug
Participants will receive MMC intravesically.
GemcitabineDrug
Participants will receive gemcitabine intravesically.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival (DFS)Time frame: Up to 6 years 7 months
Locations
123 sites in 14 countries. Site status is shown where the registry gives one.
Arkansas Urology
Little Rock, Arkansas
Genesis Research LLC 1
Los Alamitos, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
University of California Irvine Medical Center
Orange, California
University of California San Francisco
San Francisco, California
Genesis Research LLC
Torrance, California
Colorado Clinical Research
Lakewood, Colorado
Florida Urology Partners
Riverview, Florida
Northwestern University
Chicago, Illinois
UroPartners
Chicago Ridge, Illinois
Urology of Indiana
Carmel, Indiana
First Urology, PSC
Jeffersonville, Indiana
Wichita Urology Group
Wichita, Kansas
Comprehensive Urology
Royal Oak, Michigan
Specialty Clinical Research of St Louis
St Louis, Missouri
Associated Medical Professionals
Syracuse, New York
The Urology Group
Cincinnati, Ohio
Central Ohio Urology Group
Gahanna, Ohio
Centers for Advanced Urology LLC d b a MidLantic Urology
Bala-Cynwyd, Pennsylvania
Ralph H. Johnson Veterans Affairs Medical Center
Charleston, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Low Country Urology Clinics
North Charleston, South Carolina
Urology Associates
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Urology Austin
Austin, Texas
Urology Clinics of North Texas
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Houston Metro Urology
Houston, Texas
Spokane Urology
Spokane, Washington
Clinica Santa Isabel
Buenos Aires, Argentina
Investigaciones Clinico Moleculares (ICM)
CABA, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
Córdoba, Argentina
Centro Urologico Profesor Bengio
Córdoba, Argentina
Hospital Privado de la Comunidad
Mar del Plata, Argentina
AZ Sint-Jan
Bruges, Belgium
Cliniques Universitaires Saint Luc
Brussels, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
Algemeen ziekenhuis Maria Middelares
Ghent, Belgium
Algemeen Ziekenhuis Delta
Roeselare, Belgium
Fundacao Pio XII
Barretos, Brazil
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.